EGFR and brain neoplasm: Several studies have pointed out that activation of compensatory pathways that generate multiple inputs to downstream phosphatidylinositol-3-kinase (PI3K) signaling may confer insensitivity to EGFR-targeted therapies, unraveling new opportunities for multitargeting in malignant and resistant brain tumors [9].